EYENOVIA INC (EYEN)

US30234E1047 - Common Stock

0.7499  -0.07 (-8.65%)

After market: 0.7688 +0.02 (+2.52%)

News Image
3 days ago - Chartmill

Keep an eye on the top gainers and losers in Thursday's session, as they reflect the most notable price movements.

Keep an eye on the top gainers and losers in Thursday's session, as they reflect the most notable price movements.

News Image
3 days ago - Chartmill

Thursday's session: top gainers and losers

Keep an eye on the top gainers and losers in Thursday's session, as they reflect the most notable price movements.

News Image
4 days ago - Chartmill

Thursday's session: gap up and gap down stocks

Traders are paying attention to the gapping stocks in Thursday's session. Let's dive into which stocks are experiencing notable gaps.

News Image
4 days ago - Chartmill

Thursday's pre-market session: top gainers and losers

What's going on in Thursday's pre-market session

News Image
4 days ago - InvestorPlace

EYEN Stock Earnings: Eyenovia Misses EPS, Misses Revenue for Q1 2024

EYEN stock results show that Eyenovia missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024.

News Image
4 days ago - BusinessInsider

EYEN Stock Earnings: Eyenovia Misses EPS, Misses Revenue for Q1 2024

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Eyenovia (NASDAQ:EYEN) just reported results for the first quarter of 2024.Eyen...

News Image
4 days ago - Eyenovia, Inc.

Eyenovia Reports First Quarter 2024 Financial Results and Provides Updates on its Myopia Phase III Program and its Two FDA Approved Commercial Products, Mydcombi and Clobetasol

Remains on track towards accelerating development of its late-stage product candidate in the multi-billion-dollar pediatric progressive myopia market,...

News Image
25 days ago - Eyenovia, Inc.

Eyenovia Provides Clinical and Scientific Update on FDA-Approved Products Mydcombi™ and Clobetasol Propionate Ophthalmic Suspension

Company announces results from a Phase IV study of Mydcombi designed to characterize the efficacy and duration of the lowest deliverable dose (one 8µL...

News Image
a month ago - Eyenovia, Inc.

Eyenovia Announces Updated Strategy and Corporate Priorities to Focus on Shareholder Value Generation and Immediate Commercial Opportunities

Company focusing on multi-billion dollar opportunity in pediatric progressive myopia represented by MicroPine, with interim analysis planned for 4Q 2024...

News Image
2 months ago - Eyenovia, Inc.

Eyenovia to Feature its Suite of Commercial Products and the Optejet Dispenser at Upcoming National Eyecare Meetings

Company to demonstrate Mydcombi™ and Avenova® and Share Data for Clobetasol Propionate Ophthalmic Suspension 0.05% at the American Society of Cataract and...

News Image
2 months ago - Market News Video

Tuesday 4/2 Insider Buying Report: EYEN, GTN

News Image
2 months ago - InvestorPlace

EYEN Stock Earnings: Eyenovia Misses EPS, Misses Revenue for Q4 2023

EYEN stock results show that Eyenovia missed analyst estimates for earnings per share and missed on revenue for the fourth quarter of 2023.

News Image
2 months ago - BusinessInsider

EYEN Stock Earnings: Eyenovia Misses EPS, Misses Revenue for Q4 2023

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Eyenovia (NASDAQ:EYEN) just reported results for the fourth quarter of 2023.Eye...

News Image
2 months ago - Eyenovia, Inc.

Eyenovia Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update

Announced FDA approval of clobetasol propionate ophthalmic suspension 0.05% for post-operative pain and inflammation following ocular surgery Reacquired...

News Image
2 months ago - Eyenovia, Inc.

NovaBay Pharmaceuticals and Eyenovia to Co-Promote Prescription Ophthalmic Products to U.S. Eyecare Professionals

EMERYVILLE, Calif. and NEW YORK, March 13, 2024 (GLOBE NEWSWIRE) -- NovaBay Pharmaceuticals, Inc. (NYSE American: NBY) and Eyenovia, Inc. (Nasdaq: EYEN)...

News Image
2 months ago - Eyenovia, Inc.

Eyenovia to Report Fourth Quarter 2023 Results and Provide Business Update on Monday, March 18th

Company to host an investor conference call and webcast at 4:30pm EDT...

News Image
3 months ago - Formosa Pharmaceuticals

Formosa Pharmaceuticals and AimMax Therapeutics Receive FDA Approval for Clobetasol Propionate Ophthalmic Suspension 0.05%, for the Treatment of Post-Operative Inflammation and Pain Following Ocular Surgery

/PRNewswire/ -- Taiwan-based Formosa Pharmaceuticals (6838.TWO) and AimMax Therapeutics (United States) announced today that the U.S. Food and Drug...

News Image
3 months ago - Seeking Alpha

Upcoming FDA decision: Eyenovia’s APP13007

Eyenovia's (EYEN) APP13007 is coming up for a FDA decision next week. Will the drug win approval?

News Image
3 months ago - Seeking Alpha

FDA approves Eyenovia manufacturing facility in Redwood City (NASDAQ:EYEN)

Eyenovia (EYEN) said the FDA has approved its facility in Redwood City, Calif., as a commercial manufacturing facility. Read more here.

News Image
3 months ago - Eyenovia, Inc.

Eyenovia Announces FDA Approval of Redwood City as Commercial Manufacturing Facility

Redwood City, California to complement Eyenovia’s facility in Reno, Nevada as well as its contract manufacturer, Coastline International, to produce...

News Image
4 months ago - Eyenovia, Inc.

Eyenovia Re-Acquires Development and Commercialization Rights to MicroPine in the U.S. and Canada

MicroPine, currently in late phase III for pediatric progressive myopia, to complement Eyenovia’s commercial-stage asset, Mydcombi, as well as its...

News Image
5 months ago - InvestorPlace

7 Promising Penny Stocks With the Potential to Defy Expectations

While market speculation can get extremely dangerous, those who understand the risks may like these high-potential penny stocks.